BioRestorative Therapies (BRTX) Stock Statistics & Valuation Metrics

BioRestorative Therapies has a market cap or net worth of $6.40M. The enterprise value is $745.93K.

BioRestorative Therapies has 25,478,170 shares outstanding. The number of shares has decreased by -2.65% in one year.

BioRestorative Therapies’s return on equity (ROE) is -39.92 and return on invested capital (ROIC) is -4386.10%.

The current PE Ratio of BioRestorative Therapies is ―. BioRestorative Therapies’s PEG ratio is -0.02.

In the last 12 months, BioRestorative Therapies had revenue of 359.70K and earned -14.24M in profits. Earnings per share was -1.58.

In the last 12 months, operating cash flow was -10.79M and capital expenditures -72.80K, giving a free cash flow of -10.86M billion.

BioRestorative Therapies pays an annual dividend of ―, resulting in a dividend yield of ―

BioRestorative Therapies upcoming earnings date is May 20, 2026, After Close (Confirmed).

BioRestorative Therapies as a current ratio of 0.84, with Debt / Equity ratio of 0.00%

In the past 12 months, BioRestorative Therapies has paid 0.00 in taxes.

BioRestorative Therapies EV to EBITDA ratio is -0.59, with an EV/FCF ratio of -0.83.

BioRestorative Therapies has $2.95M in cash and marketable securities with $0.00 in debt, giving a net cash position of $2.95M billion.

Gross margin is 64.05%, with operating margin of -4350.05%, and net profit margin of -3959.40%.

The average price target for BioRestorative Therapies is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy